Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
Revelation Biosciences (NASDAQ:REVB) reported financial results for the three and six months ended June 30, 2026, and highlighted progress with its Gemini program. The company formed and expanded an Acute Kidney Injury (AKI) Advisory Board for its planned Phase 2/3 Gemini AKI trial and continued study start-up activities. An independent market assessment indicated a potential $94 billion total addressable market for Gemini across target indications.
As of June 30, 2026, Revelation held $11.5 million in cash and cash equivalents, up from $10.7 million at December 31, 2025, primarily from January 2026 warrant inducement proceeds. According to Revelation, existing cash is expected to fund operations through the first quarter of 2027. For Q2 2026, net cash used in operating activities was $2.6 million versus $1.9 million a year earlier. Net loss for Q2 2026 was $3.3 million (basic and diluted loss per share of $0.87) compared with $2.4 million ($28.04 per share) in Q2 2025. For the six-month period, net loss was $6.3 million, or $3.41 per share, versus $4.5 million, or $54.39 per share, in the prior-year period.
Total operating expenses for Q2 2026 were $3.7 million, driven by research and development expense of $1.9 million and general and administrative expense of $1.7 million. At June 30, 2026, total assets were $12.5 million and stockholders' equity was $10.1 million, with 3,908,420 common shares outstanding, up from 1,583,969 at year-end 2025.
Revelation Biosciences (NASDAQ: REVB) announced that its Board Compensation Committee approved three inducement equity grants on July 15, 2026, totaling 108,000 restricted stock units (RSUs) for three newly hired non-executive employees. The RSUs, issued under the 2026 Equity Inducement Plan, are intended as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest in equal quarterly installments over two years, beginning on October 15, 2026 and ending on July 15, 2028, contingent on continued employment or service. According to Revelation Biosciences, the company is a clinical-stage life sciences firm developing inflammation-rebalancing therapies using its proprietary formulation, Gemini, across multiple acute and chronic indications.
Revelation Biosciences (NASDAQ: REVB) announced that its Board has adopted a stockholder rights plan under a Rights Agreement dated July 10, 2026, with Continental Stock Transfer & Trust as rights agent, and declared a dividend of one Right per outstanding common share to holders of record on July 21, 2026.
The Rights become exercisable if any person or group acquires 10% or more of common stock (or 15% for certain passive institutional investors) without prior Board approval. Each Right will allow the purchase of 1/1000 of a share of Series B Junior Participating Preferred Stock at an exercise price of $20.00, subject to adjustment, and, if triggered, enables other holders to buy additional common shares or equivalents at a substantial discount. The Rights initially trade with the common stock and are not separately exercisable. The plan expires on the first anniversary of adoption, or on the third anniversary if approved by stockholders, unless earlier redeemed or exchanged. According to Revelation, the plan aims to ensure all stockholders realize full value and is not intended to block fair acquisition offers or affect current financial condition or operations.
Revelation Biosciences (NASDAQ:REVB), a clinical-stage life sciences company, expanded its Acute Kidney Injury (AKI) Advisory Board ahead of a planned Phase 2/3 trial of Gemini. Two internationally recognized leaders in intensive care and nephrology, Dr. Peter Pickkers and Dr. Lui Forni, join to help guide clinical strategy and study design.
Revelation Biosciences (NASDAQ:REVB) issued a corporate update outlining the development path for its lead drug Gemini in acute kidney injury (AKI) and providing 2025 financials.
The FDA agreed that positive data from a single ~300‑patient Phase 2/3 adaptive study using a composite endpoint of death and/or dialysis could support an NDA. Revelation reported $10.7 million in cash at December 31, 2025, believes funding extends into Q1 2027, and reduced annual net loss to $8.9 million.
Revelation Biosciences (NASDAQ:REVB) reported results for the quarter ended March 31, 2026, highlighting an FDA agreement on a single adaptive Phase 2/3 study for Gemini and presentation of additional PRIME Study data at AKI & CRRT 2026. Cash and proceeds totaled $14.1M, including $6.7M from a January warrant inducement. Net cash used in operations was $3.2M and net loss was $3.0M ($2.71 per share). The company believes current resources fund operations through Q1 2027.
Revelation Biosciences (NASDAQ:REVB) announced the formation of an Acute Kidney Injury (AKI) Advisory Board to guide its upcoming Phase 2/3 AKI clinical trial of Gemini. The panel includes internationally recognized nephrologists and critical care physicians led by Principal Investigator Laurence Busse, MD.
The advisory board will inform study design, monitor progress, and support clinical strategy to address the unmet medical need in AKI and advance Gemini's development program.
Revelation Biosciences (NASDAQ:REVB) presented additional PRIME study data showing that a single dose of Gemini durably normalized cellular inflammation and restored immunocompetence in stage 3–4 CKD patient samples.
Key findings: >85% had elevated cytokines predose, >60% had IL-1b/IL-6 elevations, and Gemini reduced elevated cytokines and restored LPS responsiveness through 7 days post‑dose.
Revelation Biosciences (NASDAQ:REVB) will participate in a fireside chat at the 38th Annual Roth Conference on March 24, 2026 at 2:00 p.m. PT in Dana Point, CA.
The event will be webcast live and later archived in the Investors section of Revelation Biosciences' website at www.RevBiosciences.com.
Revelation Biosciences (NASDAQ:REVB) will participate in the 38th Annual Roth Conference in Dana Point, CA, on March 23–24, 2026. CEO James Rolke and CFO Chester S. Zygmont III will attend, and the company will hold a fireside chat on March 24, 2026 at 2:00 p.m. PT.
The fireside chat will be webcast live and later posted in the Investors section at www.RevBiosciences.com. Investors seeking meetings should contact their Roth representative.